Un calendrier alléchant - ACHAT - OC 18€
Suite à sa conférence téléphonique d’hier post S1 2016, nous revenons ce matin sur les prochains catalyseurs CT. Brièvement, malgré une augmentation significative des coûts de R&D, la trésorerie actuelle (243,6m€ fin S1) permet d’avoir une bonne visibilité. Le point clé de cette publication selon nous réside dans le calendrier prévisionnel d’un point de vue clinique. INNATE confirme ainsi avoir un « newsflow » dense pour cette fin d’année, avec en point culminant les résultats cliniques de lirilumab en combinaison avec nivolumab de BMS (sécurité et efficacité). Nous valorisons à ce stade essentiellement lirilumab et monalizumab, le reste du portefeuille de plus en plus attractif se révèle être des options libres à notre modèle de valorisation. Nous maintenons notre recommandation à ACHAT avec un objectif de cours pour l’instant inchangé de 18€.Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.